Response by van der Bruggen et al to Letter Regarding Article, “Bone Morphogenetic Protein Receptor Type 2 Mutation in Pulmonary Arterial Hypertension: A View on the Right Ventricle”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
We would like to thank Dr Kataoka and colleagues for their interest in our recent publication.1
We agree with the authors’ notion that our population differs from the published literature in respect to hemodynamic burden.1 No significant difference could be observed in our patients carrying a mutation in the bone morphogenetic protein type 2 receptor (BMPR2) compared with noncarriers. This might be explained by the higher prevalence of cytoplasmic tail mutations in our cohort (25%) compared with the French cohort (13%), as already explained in the original article.2
Despite the similar …